3 edition of Selected abstracts on recent advances in the systematic therapy of genitourinary malignancies found in the catalog.
Selected abstracts on recent advances in the systematic therapy of genitourinary malignancies
Douglas E. Johnson
by U.S. Dept. of Health and Human Services, Public Health Service, National Cancer Institute, U.S. G.P.O., distributor in [Bethesda, MD], Washington, D.C
Written in English
|Other titles||Recent advances in the systematic therapy of genitourinary malignancies.|
|Statement||Douglas E. Johnson [and] Christopher J. Logothetis.|
|Contributions||Logothetis, Christopher J., National Cancer Institute (U.S.), International Cancer Research Data Bank.|
|The Physical Object|
|Pagination||vii, 60, 18, 5 p. ;|
|Number of Pages||60|
Abstract Background. Metastatic breast cancer is a complex disease that is traditionally treated using systemic therapy. There is mounting evidence that locoregional therapy (LRT), such as resection of the primary tumour and/or localised radiotherapy could be associated with improvements in survival. Recent advances in pediatric bladder malignancies [version 1; peer review: 2 approved] Abstract Urothelial pediatric neoplasms are relatively rare. Papillary urothelial neoplasms of low malignant potential (PUNLMPs) and rhabdomyosarcoma (RMS) are the most common bladder malignancies in the pediatric radiation therapy.
The desmoid tumor is a locally aggressive proliferative disease within the family of soft-tissue sarcomas. Despite its relatively good prognosis, the clinical management of desmoid tumors requires constant multidisciplinary evaluation due to its highly variable clinical behavior. Recently, active surveillance has being regarded as the appropriate strategy at diagnosis, as indolent persistence. This work provides a systematic review of the literature from January to April pertaining to the incidence, pathophysiology, diagnosis, and treatment of osteonecrosis of the jaw (ONJ), and.
Wen-Liang Yu, Zi-Chun Hua, Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety—A Systematic Review with Meta-Analysis, Cancers, /cancers, 11, 1, (47), (). (7)Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: @ Medical imaging of the 3 most common genitourinary (GU) cancers-prostate adenocarcinoma, renal cell carcinoma, and urothelial carcinoma of the bladder-has evolved.
Curse you, Jack Dalton!
Considerations on church-authority; occasioned by Dr. Balguys sermon, on that subject; preached at Lambeth Chapel,and published by order of the Archbishop.
history of the life and reigne of Richard the Third.
The Land For The People
To speak of love / Ernest Pallascio-Morin.
Insight Guides Berlin (Insight City Guides, No 135a)
Elements of electromagnetics.
Texas, the Dark Corner of the Confederacy
Agility and flexibility
art of the Hittites.
Teddy Bear cut & use stencils
dialogue of energy
Get this from a library. Selected abstracts on recent advances in the systematic therapy of genitourinary malignancies. [Douglas E Johnson; Christopher J Logothetis; National Cancer Institute (U.S.); International Cancer Research Data Bank.].
Call for Abstracts Program Abstracts will be selected for poster presentation at the conference. Please submit abstracts via e-mail to [email protected] The deadline for submission is Aug Authors of selected abstracts will be notified via e-mail by Septem Friday, Octo Read the original article in full on FResearch: Recent advances in pediatric bladder malignancies Read the latest article version by Roberto Iglesias Lopes, Marcos Figueiredo Mello, Armando J.
Lorenzo, at by: 1. In genitourinary malignancies, immunotherapy has revolutionized the approach to metastatic renal cell carcinoma (RCC) and advanced urothelial carcinoma in the first- and second-line settings. Data from randomized clinical trials in the metastatic setting have not specifically investigated the local effect of immunotherapy, and little Cited by: 6.
Aims and Scope. Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices).
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment A better understanding of the biology of urologic malignancies has led to a rapid change in their therapeutic landscape.
With the approval of several novel agents in each of these tumors, understanding appropriate patient selection, mechanisms of Cited by: 9. Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies Expert Opin. Biol. Ther. () 14 (12) 3 Expert Opin. Biol.
Ther. Downloaded from by. Abstract Most cancer patients are treated with some combination of surgery, radiation, and chemotherapy. Despite recent advances in local therapy with curative intent, chemotherapeutic treatments for metastatic disease often remain unsatisfying due to severe side effects and incomplete long-term remission.
His recent studies combining immunotherapy with more standard treatment have been active and demonstrated the ability to maintain a robust immunologic response. Dahut is also the Scientific Director for Clinical Research at CCR. Ravi A. Madan, M.D. is the Clinical Director of the Genitourinary Malignancies Branch.
His research focuses on. Abstract The treatment of genitourinary malignancies has dramatically evolved over recent years. Renal cell carcinoma, urothelial carcinoma of the bladder, and prostate adenocarcinoma are the most commonly encountered genitourinary malignancies and represent a heterogeneous population of cancers, in both histology and approach to treatment.
The treatment of genitourinary malignancies has dramatically evolved over recent years. Renal cell carcinoma, urothelial carcinoma of the bladder, and prostate adenocarcinoma are the most commonly. Genitourinary Malignancies. John G. Connolly.
Abstract. Early diagnosis of malignant disease in the genitourinary system means a better opportunity for cure. The family physician must be aware of the signs and symptoms of GU tumors in all stages, and the investigations required to establish a.
Abstract: Bisphosphonates are the standard of care for preventing skeletal morbidity in patients with malignant bone disease. In this setting, zoledronic acid (intravenous; 4 mg monthly) is approved for the prevention of skeletal-related events in patients with bone lesions from multiple myeloma or bone metastases from breast cancer and other solid tumors (eg, genitourinary malignancies, lung.
The book starts with general approaches in palliative radiation oncology that are followed by a section that focuses on common symptoms in palliative care and their management. The next section of the book is devoted to site and disease-specific evaluation, intervention, and management.
Abstract Background. Chemotherapy (CT) plays a vital role as conversion treatment for initially unresectable or borderline resectable colorectal cancer (CRC). Targeted therapies are recommended with CT for conversion therapy; however, their role in conversion of. SYSTEMATIC REVIEW OF LASER THERAPY FOR GENITOURINARY SYNDROME OF MENOPAUSE (GSM) it was difficult to give weight to the above selected studies.
Of the 4 studies, one was based upon Erbium and the other 3 were abstract is a systematic review of published articles and there was no direct participation of human subjects Informed Consent.
Abstract: Photodynamic therapy has many treatment applications for malignant and premalignant lesions of the skin.
The basic principle involves application of a photosensitizer followed by exposure of the target tissues to light. 5-aminolevulinic acid is a natural occurring compound in.
More recent advances in computer technology have led to improvements on the 3D-CRT technique; one, in particular, being the development of intensity modulated radiation therapy (IMRT) . In contrast to 3D-CRT, which uses uniform fields, IMRT generates non-uniform fields to achieve better planning target volume coverage, while decreasing.
The advances in the diagnosis and theraphy of genitourinary cancers during the last two decades have significantly improved the prognosis and prolonged the survival of genitourinary cancer patients. The therapeutic success has been accompanied by concerns for long-term side-effects of treatments, including therapy-related second malignancies.
Aims & Scope Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology.
Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology.
Invited and unsolicited review. Ira Surolia, James Gulley, Ravi A Madan, Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies, Expert Opinion on Biological Therapy, /, 14, 12, (), ().Significant advances have been made in our understanding of the molecular and cellular events which contribute to the generation of GU malignancies.
At the same time, similar advances have been made in the clinical arena which have improved the diagnosis and treatment of urologic cancers.Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers.
Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary .